PBI19 Cost-Effectiveness Analysis of Adalimumab Biosimilar for Rheumatoid Arthritis in Brazil Compared to Delayed Biologic Treatment Initiation
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.097
https://www.valueinhealthjournal.com/article/S1098-3015(20)32353-6/fulltext
Title :
PBI19 Cost-Effectiveness Analysis of Adalimumab Biosimilar for Rheumatoid Arthritis in Brazil Compared to Delayed Biologic Treatment Initiation
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32353-6&doi=10.1016/j.jval.2020.08.097
First page :
Section Title :
Open access? :
No
Section Order :
10070